{"log_id": 2603567976915559470, "direction": 0, "words_result_num": 34, "words_result": [{"probability": {"variance": 0.000464, "average": 0.993339, "min": 0.873399}, "location": {"width": 825, "top": 241, "height": 30, "left": 204}, "words": "抗HBe血清转换)。第240周时,两治疗组 HBSAG转阴率均达到9%,最初随机接受富"}, {"probability": {"variance": 6e-06, "average": 0.998541, "min": 0.988037}, "location": {"width": 823, "top": 273, "height": 27, "left": 206}, "words": "马酸替诺福韦二吡呋酯的患者抗HBs血清转换率达7%,最初随机接受阿德福韦酯的受"}, {"probability": {"variance": 2.4e-05, "average": 0.995068, "min": 0.988411}, "location": {"width": 100, "top": 304, "height": 25, "left": 205}, "words": "试者达9%"}, {"probability": {"variance": 2e-06, "average": 0.99903, "min": 0.995137}, "location": {"width": 817, "top": 351, "height": 28, "left": 205}, "words": "两项研究中,最初随机接受治疗的641例受试者中有328名受试者继续接受富马酸替"}, {"probability": {"variance": 0.00652, "average": 0.985237, "min": 0.487713}, "location": {"width": 823, "top": 382, "height": 27, "left": 206}, "words": "诺福韦二吡呋酯单药开放性治疗,其肝组织学穿刺数据可用于基线、第48周和第240"}, {"probability": {"variance": 3e-06, "average": 0.99787, "min": 0.994958}, "location": {"width": 90, "top": 413, "height": 25, "left": 205}, "words": "周的分析"}, {"probability": {"variance": 5.6e-05, "average": 0.996921, "min": 0.958473}, "location": {"width": 816, "top": 439, "height": 29, "left": 205}, "words": "第240周肝穿刺数据亚组受试者与继续接受富马酸替诺福韦二吡呋酯开放性治疗无肝"}, {"probability": {"variance": 1e-05, "average": 0.998467, "min": 0.985266}, "location": {"width": 774, "top": 469, "height": 27, "left": 204}, "words": "穿刺数据的受试者之间,无明显可能会影响第240周组织病理学检查结果的差异"}, {"probability": {"variance": 1.1e-05, "average": 0.998223, "min": 0.981697}, "location": {"width": 825, "top": 498, "height": 27, "left": 213}, "words": "28名接受评价的受试者中,第48周和第240周组织病理学应答率分别为80%和88%"}, {"probability": {"variance": 4.4e-05, "average": 0.99616, "min": 0.967746}, "location": {"width": 745, "top": 525, "height": 27, "left": 205}, "words": "基线时无肝硬化受试者中( Ishak纤维化评分0~4),92%(216/235)和95%"}, {"probability": {"variance": 0.007696, "average": 0.980221, "min": 0.44236}, "location": {"width": 809, "top": 554, "height": 28, "left": 223}, "words": "223/235)受试者分别在第48周和第240周的 Ishak纤维化评分得到改善或无变化"}, {"probability": {"variance": 7.6e-05, "average": 0.994597, "min": 0.953327}, "location": {"width": 811, "top": 586, "height": 24, "left": 205}, "words": "基线时有肝硬化受试者中( Ishak纤维化评分5~6),97%(90/93)和99%(92/93)"}, {"probability": {"variance": 0.000803, "average": 0.991538, "min": 0.825689}, "location": {"width": 824, "top": 614, "height": 27, "left": 206}, "words": "受试者分别在第48周和第240周的 Ishak纤维化评分得到改善或无变化。基线时有肝"}, {"probability": {"variance": 0.000284, "average": 0.994306, "min": 0.902737}, "location": {"width": 826, "top": 643, "height": 26, "left": 206}, "words": "硬化受试者,在第48周和第240周分别有29%(27/93)和72%(67/93)受试者转归"}, {"probability": {"variance": 7.2e-05, "average": 0.995941, "min": 0.962197}, "location": {"width": 807, "top": 672, "height": 27, "left": 210}, "words": "shak纤维化评分至少下降2分。无法对未参加该亚组分析的维持研究人群得出确切"}, {"probability": {"variance": 0, "average": 0.999511, "min": 0.99927}, "location": {"width": 47, "top": 703, "height": 24, "left": 205}, "words": "结论"}, {"probability": {"variance": 5e-06, "average": 0.998392, "min": 0.991589}, "location": {"width": 296, "top": 751, "height": 28, "left": 205}, "words": "拉米夫定耐药的慢性乙肝患者"}, {"probability": {"variance": 0.004245, "average": 0.981399, "min": 0.634821}, "location": {"width": 760, "top": 800, "height": 28, "left": 206}, "words": "研究121是一项随机双盲的活性药物对照试验,在病毒血症( HBV DNA≥1,0"}, {"probability": {"variance": 0.00262, "average": 0.976408, "min": 0.737935}, "location": {"width": 823, "top": 830, "height": 27, "left": 208}, "words": "IU/mL)、基因型检查证明有拉米夫定耐药(rM204IV+/-rtL180M)的受试者中,评"}, {"probability": {"variance": 0.001623, "average": 0.989798, "min": 0.761531}, "location": {"width": 815, "top": 859, "height": 28, "left": 207}, "words": "价富马酸替诺福韦二吡呋酯与其它抗病毒药物的安全性和有效性。有141位成人受试"}, {"probability": {"variance": 8.7e-05, "average": 0.99654, "min": 0.953646}, "location": {"width": 815, "top": 889, "height": 27, "left": 207}, "words": "者随机分配至富马酸替诺福韦二吡呋酯治疗组中,分配至该治疗组中受试者的平均年"}, {"probability": {"variance": 0.000155, "average": 0.995199, "min": 0.936551}, "location": {"width": 826, "top": 917, "height": 27, "left": 206}, "words": "龄为47岁(范围为18~73岁),74%为男性,59%为高加索人,37%为亚洲人。在基"}, {"probability": {"variance": 0.005913, "average": 0.979179, "min": 0.537953}, "location": {"width": 813, "top": 946, "height": 27, "left": 208}, "words": "线时,54%受试者为 Hbeag阴性,46%为 Hbeag阳性,56%为ALT异常。受试者在"}, {"probability": {"variance": 0.014728, "average": 0.94933, "min": 0.423403}, "location": {"width": 736, "top": 975, "height": 32, "left": 207}, "words": "基线时的平均 HBV DNA为6.4 1 logno copies/ML,平均血清ALT为71/L"}, {"probability": {"variance": 1.1e-05, "average": 0.998182, "min": 0.986779}, "location": {"width": 781, "top": 1038, "height": 28, "left": 206}, "words": "经过96周治疗后,在随机分配至富马酸替诺福韦二吡呋酯治疗组的受试者中,有"}, {"probability": {"variance": 0.002524, "average": 0.980712, "min": 0.756822}, "location": {"width": 807, "top": 1068, "height": 27, "left": 215}, "words": "26/141位受试者(89%)的 HBV DNA<400 copies/mL,79位基线时ALT异常受试"}, {"probability": {"variance": 0.000107, "average": 0.996094, "min": 0.942284}, "location": {"width": 774, "top": 1096, "height": 26, "left": 208}, "words": "者中,49位(62%)ALT复常。在随机分配至富马酸替诺福韦二吡呋酯治疗组的"}, {"probability": {"variance": 0.004904, "average": 0.980914, "min": 0.563518}, "location": {"width": 823, "top": 1125, "height": 27, "left": 208}, "words": " Hbeag阳性受试者中,在96周时,10/65位受试者(15%)出现了 Hbeag转阴,765"}, {"probability": {"variance": 0.011263, "average": 0.968337, "min": 0.360453}, "location": {"width": 811, "top": 1153, "height": 27, "left": 208}, "words": "位受试者(11%)出现了抗HBe血清转换96周时 HBV NDA低于400 copies/mL的患"}, {"probability": {"variance": 3.7e-05, "average": 0.996768, "min": 0.974953}, "location": {"width": 573, "top": 1182, "height": 26, "left": 208}, "words": "者比例,富马酸替诺福韦二吡呋酯单药治疗组和对照组相近"}, {"probability": {"variance": 3e-06, "average": 0.998728, "min": 0.992781}, "location": {"width": 816, "top": 1231, "height": 28, "left": 208}, "words": "综合分析慢性乙型肝炎的临床试验,基线时具有阿德福韦耐药相关突变的受试者数量"}, {"probability": {"variance": 0, "average": 0.999575, "min": 0.998676}, "location": {"width": 266, "top": 1261, "height": 26, "left": 208}, "words": "不足以确定该亚组中的疗效"}, {"probability": {"variance": 1.1e-05, "average": 0.997992, "min": 0.98824}, "location": {"width": 268, "top": 1360, "height": 28, "left": 208}, "words": "慢性乙肝和失代偿肝病患者"}, {"probability": {"variance": 0.097656, "average": 0.676295, "min": 0.363795}, "location": {"width": 30, "top": 1513, "height": 26, "left": 1037}, "words": "5"}], "language": 3}